Sunshine Biopharma, Inc. (SBFMW) 주식 분석

회사 개요

Sunshine Biopharma, Inc. operates as a pharmaceutical entity dedicated to the research and development of life-saving medicines across various therapeutic areas, with a specific focus on oncology and antivirals within the United States and Canadian markets. The company functions through its Prescription Generic Pharmaceuticals and Nonprescription segments, aiming to address critical healthcare needs in these regions. Although the specific sector and industry classifications are not explicitly defined in the available data, the firm's operational scope clearly positions it within the biotechnology and healthcare landscape. Regarding its scale, the company reports a market cap of N/A, an annual revenue of $36.31M, and an employee count that is listed as N/A. The absence of a quantified market cap figure alongside a revenue stream of $36.31M suggests that the company is likely in a growth or development phase where traditional valuation metrics may not yet reflect its full potential or where the market capitalization has not been disclosed in the current reporting period. The lack of employee data further limits the immediate assessment of operational scale, but the revenue figure provides a tangible indicator of its current business volume and market penetration in the pharmaceutical space.

재무 건전성

The company reported a revenue of $36.31M for the trailing twelve months, yet it recorded a net income of $-5,975,352 and an EBITDA of $-4,146,712, highlighting a significant disparity between top-line generation and bottom-line profitability. The substantial gap between the $36.31M revenue and the negative net income reveals a cost structure where operating expenses, including research and development costs, heavily outweigh gross profits, which is common for biopharma firms in early-stage development or clinical trials. Free cash flow stands at $-4,632,801, indicating that the company is currently burning cash to fund its operations and R&D initiatives rather than generating liquidity from its business activities. This negative cash flow implies limited immediate financial flexibility, necessitating reliance on existing cash reserves or external financing to sustain operations until profitability is achieved. In terms of profitability margins, the gross margin is 33.8%, while the operating margin is -19.3% and the profit margin is -16.5%, collectively indicating that while production costs are managed at a reasonable level relative to sales, overhead and R&D expenses are consuming the majority of operating profits. The balance sheet shows cash holdings of $9.12M against total debt of $812,422, resulting in a debt-to-equity ratio of 3.53, which suggests a leveraged balance sheet where equity is significantly smaller than the debt burden. Despite the high leverage indicated by the debt-to-equity ratio, the current ratio of 4.17 indicates a strong short-term liquidity position, as the company holds sufficient current assets to cover its short-term liabilities more than four times over. Return on Equity is -25.7% and Return on Assets is -9.2%, metrics that reveal that management is currently generating negative returns on both shareholder equity and the total asset base, reflecting the capital-intensive nature of the pharmaceutical sector during the development phase.

밸류에이션 평가

The trailing P/E ratio and forward P/E ratio are both listed as N/A, meaning traditional earnings-based valuation multiples are unavailable for analysis due to the company's lack of positive earnings. The price-to-book ratio is 0.02, which indicates that the market values the company's equity at a fraction of its book value, suggesting a deep discount relative to the net assets recorded on the balance sheet. Since the price-to-sales ratio and EV/EBITDA are also N/A, alternative valuation metrics that typically provide insight into revenue or cash-flow multiples are not currently applicable for direct comparison with profitable peers. The stock's 52-week high and low are both recorded at $0.13, meaning the current trading price sits exactly at the midpoint of this range with no deviation from the historical extremes provided in the data. The beta value is 1.60, which implies that the stock's price volatility is 60% higher than the broader market, reflecting the high risk and sensitivity typical of small-cap biopharmaceutical stocks.

Growth & Income

Revenue growth year-over-year is -10.6%, while earnings growth is N/A due to the absence of profitable earnings to measure, indicating that the company is currently contracting in terms of top-line revenue. The lack of positive earnings growth relative to declining revenue underscores the challenges the company faces in scaling its business while managing significant operating losses. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, instead choosing to reinvest any available earnings or capital into its research and development pipeline rather than returning cash to shareholders. This growth and income profile is characterized by negative revenue growth and a complete absence of dividend income, positioning the investment primarily as a high-risk, high-potential-reward equity in the biotechnology sector rather than an income-generating asset.